High Content & Phenotypic Screening 2017 Keynote Speakers

Lorenz Mayr Vice President, AstraZeneca Ltd Lorenz is working as Vice President, Reagents & Assay Development with global responsibility for generation of biological reagents and assay development activities at AstraZeneca. This includes generation of proteins and cell lines for hit finding, hit-to-lead and lead optimisation activities including structure & biophysics for all therapeutic areas, generation of tool antibodies, transgenic animals, stem/primary cells as tools for target validation and lead optimisation. His department is responsible for the development of biochemical, cell-based and phenotypic assays at AstraZeneca. Before that, he was working as Executive Director at Novartis in Basel/Switzerland, at Bayer in Leverkusen & Wuppertal/Germany and at the MIT/Whitehead Institute in Cambridge/MA (U.S.A.). He has published more than 50 papers in peer-reviewed journals and serves on several editorial and scientific advisory boards, including two terms at the Board of Directors for SBS (2004-2011) and has been working as the Conference Chair of the MipTec Conference, Europe’s largest drug discovery event.
Jeffrey Morgan Professor of Medical Science and Engineering, Brown University Jeff Morgan is Professor of Medical Science and Engineering at Brown University. A graduate of Syracuse (BS) and Harvard (PhD) with postdoctoral training at MIT and the Whitehead Institute, he was on the faculty of Harvard Medical School prior to Brown. Dr. Morgan has received numerous awards and patents for his research in gene therapy and tissue engineering and he has co-founded three companies including his latest, Microtissues, Inc (www.microtissues.com). Among his inventions are the 3D Petri Dish®, a technology for growing cells in three dimensions with applications in toxicity testing, drug discovery and tissue engineering. Dr. Morgan has published over 130 peer-reviewed papers, reviews and chapters and has edited two books and is an inventor of 12 U.S. and international patents. He is a Fellow of the National Academy of Inventors as well as a Fellow of the American Institute of Medical and Biological Engineering.
Leo Price CEO, Ocello B.V Leo Price was trained as a cell biologist and has held positions in London, San Diego, Amsterdam and Utrecht in cancer research. From 2005, he ran a research group at Leiden University, where he developed 3D tissue culture based screening technology. This technology was spun off as OcellO, a contract research company that develops physiologically relevant models of disease and uses these to offer compound screening and profiling services for the drug discovery industry.